Novo Nordisk A/s

Zhiru Yang

Henrik Oestergaard

Jianhe Chen

Prafull S Gandhi

Laust Bruun Johnsen

Rong Zhou

Karina Thorn

Per J Greisen

Mikkel Nors Harndahl

Bjarne Gram Hansen

Morten Groenbech Rasch

Haisun Zhu

Anders Svensson

Eva Johansson

The present invention relates to improved procoagulant antibodies including bispecific antibodies capable of binding to coagulation Factor IX (FIX) or the activated form thereof Factor IXa (FIXa) and optionally Factor X (FX) and the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A.

Procoagulant antibodies

The present invention relates to multispecific procoagulant antibodies capable of binding to coagulation Factor IX (FIX) and/or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and/or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes or parts thereof and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A as well as kits, methods of manufacture and methods of use.

Growing community of inventors

Beijing, China

Zhiru Yang